Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
Status:
Unknown status
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
IBI306 is a fully human monoclonal antibody that binds proprotein convertase
substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density
lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and
low-density lipoprotein cholesterol（LDL-C）uptake. In phase I study IBI306 was shown to be
safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and
lipoprotein (a) in healthy subjects. This study is a randomized, double-blind,
placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the safety and
tolerability of a novel PCSK-9 anti-body, IBI306, in Chinese patients with
hypercholesterolemia.